SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
January 28, 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
January 23, 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB to host webinar event to discuss Phase 1 clinical trial topline results
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
November 06, 2024 17:05 ET
|
SAB Biotherapeutics, Inc.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
October 31, 2024 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 09:00 ET
|
Kriya Therapeutics, Inc.
– Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
TNDM Shareholder Alert: Investors with Large Losses Should Contact Robbins LLP for Information About Recovery Against Tandem Diabetes Care, Inc.
September 21, 2023 18:52 ET
|
Robbins LLP
SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Tandem Diabetes...
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
August 22, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse...
Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients
June 25, 2021 11:30 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Nemaura Medical Launches BEAT®diabetes Program and Its Novel proBEAT™ Non-Invasive, Daily-Wear Adhesive Glucose Monitor
December 17, 2020 08:00 ET
|
Nemaura Medical Inc.
LOUGHBOROUGH, England, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...
Nemaura Medical Licenses Validated Mobile Application to Create Powerful Diabetes Prevention and Management Suite of Products
September 21, 2020 08:00 ET
|
Nemaura Medical Inc.
Clinically proven app from Healthimation, LLC, to be paired with Company’s proBEAT™ non-invasive CGM system solution to offer convenient and effective management of pre-diabetes and Type 2 diabetes ...